



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

651. MULTIPLE MYELOMA AND PLASMA CELL DYSCRASIAS: BASIC AND TRANSLATIONAL

Late B Cell-Specific Dis3-Knockout Mice Do Not Develop Plasma Cell Neoplasm

Hiroto Ohguchi¹, Yasuyo Ohguchi¹, Sho Kubota, PhD², Takako Yokomizo-Nakano², Ai Hamashima², Kimi Araki, PhD³, Goro Sashida, MD PhD²

¹Division of Disease Epigenetics, IRDA, Kumamoto University, Kumamoto, Japan

²Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan

³Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan

Recent advances in next-generation sequencing have unveiled genetic abnormalities associated with multiple myeloma (MM). Of note, *DIS3* mutations have been observed in ~10% of MM patients, and 13q deletion including the *DIS3* gene locus are present in ~40% of MM patients. Furthermore, *DIS3* mutations/deletions have been shown to be associated with poorer prognosis in MM. Regardless of high incidence of *DIS3* mutations/deletions and their relation to adverse outcome, the roles of *DIS3* in hematopoiesis and myelomagenesis remains incompletely understood. Here we show that *Dis3* is required for normal hematopoiesis and *Dis3* deficiency is not sufficient for the development of plasma cell neoplasm in mice.

We first explored *DIS3* functions in hematopoiesis by generating *Dis3* conditional knockout (KO) mice (*Dis3*^{fl/fl};Mx-Cre). To avoid possible effects of *Dis3* deficiency on nonhematopoietic cells, we transplanted bone marrow (BM) cells from *Dis3*^{fl/fl};Mx-Cre mice into lethally irradiated CD45.1⁺ recipient mice. Four weeks after transplantation, we knocked out *Dis3* by inducing Cre recombinase via an intraperitoneal injection of Poly(I:C). The deletion of *Dis3* in BM cells was confirmed by genotyping and quantitative real time PCR. Importantly, loss of *Dis3* in hematopoietic cells resulted in severe pancytopenia at 2 weeks after *Dis3* deletion. Consistent with this observation, *Dis3* KO mice showed reduced BM counts with relative preservation of mature lymphocytes. A flow cytometric analysis of the BM exhibited lower frequencies of Lin⁻Sca-2⁺c-Kit⁺ (LSK), hematopoietic stem, and multipotent progenitor cells in *Dis3* KO mice compared with wild-type (WT) mice. *Dis3* KO mice also exhibited lower frequencies of common myeloid progenitors, granulocyte/macrophage progenitors, and megakaryocyte/erythroid progenitors compared with WT mice. A frequency of common lymphoid progenitors (CLPs) was comparable between WT and *Dis3* KO mice, whereas absolute numbers of CLPs were significantly reduced in *Dis3* KO mice than in WT mice. These results indicate that *Dis3* is indispensable for normal hematopoiesis, and LSK and myeloid progenitor cells are more dependent on *Dis3* than lymphoid progenitor cells.

We next examined whether loss-of-function of *Dis3* drives plasma cell neoplasm. To do so, we crossed *Dis3*^{fl/wt} or *Dis3*^{fl/fl} mice with Cgamma1-Cre mice and generated late B cell-specific *Dis3* KO mice by activating Cre recombinase via immunizing with NP-CGG in these compound mice. However, these mice did not develop any B cell malignancies and shorten the survival compared with WT mice. In the samples of MM patients, the frequency of *DIS3* mutations is significantly higher in t(14;16) samples than in those without t(14;16) (Walker et al. Blood 2018). We therefore utilized t(14;16) model mice (c-Maf TG) (Morito et al. Cancer Res 2011) and generated c-Maf TG; *Dis3*^{fl/wt};Cgamma1-Cre and c-Maf TG; *Dis3*^{fl/fl};Cgamma1-Cre mice. As reported (Morito et al. Cancer Res 2011), a small fraction of mice with c-Maf TG developed B cell lymphoma after a long latency. However, the addition of *Dis3* KO did not increase the frequency of B cell lymphoma and shorten the survival compared with c-MAF TG mice. These results indicate that only *Dis3* deficiency and the combination of c-Maf overexpression and *Dis3* deficiency do not develop plasma cell neoplasm and suggest that additional oncogenic events are necessary for myelomagenesis. Further investigations are required for elucidating the mechanisms of how loss-of-function of *DIS3* is involved in the development of MM.

Disclosures No relevant conflicts of interest to declare.

<https://doi.org/10.1182/blood-2023-173003>